Bausch + Lomb Corporation (BLCO)

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
U.S. and Puerto Rico Revenue	-	2.55B	2.41B
U.S. and Puerto Rico Revenue Growth	-	5.51%	24.77%
Total International Revenue	-	2.56B	2.38B
Total International Revenue Growth	-	7.44%	7.51%
Revenue (Total)	5.89B	5.10B	4.79B
Revenue (Total) Growth	15.44%	6.47%	15.56%

Revenue Breakdown

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Vision Care Revenue	2.98B	2.92B	2.74B
Vision Care Revenue Growth	1.88%	6.72%	7.71%
Surgical Revenue	908.00M	894.00M	843.00M
Surgical Revenue Growth	1.57%	6.05%	9.91%
Ophthalmic Pharmaceuticals Revenue	1.32B	1.28B	1.21B
Ophthalmic Pharmaceuticals Revenue Growth	2.96%	6.20%	44.62%
Revenue (Other)	680.61M	-	-
Revenue (Total)	5.89B	5.10B	4.79B
Revenue (Total) Growth	15.44%	6.47%	15.56%

Revenue Breakdown 2

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Pharmaceuticals Revenue	1.13B	1.08B	969.00M
Pharmaceuticals Revenue Growth	4.07%	11.56%	56.80%
Devices Revenue	1.95B	1.92B	1.80B
Devices Revenue Growth	1.67%	6.78%	9.09%
OTC Revenue	1.87B	1.83B	1.72B
OTC Revenue Growth	1.96%	6.38%	7.01%
Branded and Other Generics Revenue	237.00M	243.00M	281.00M
Branded and Other Generics Revenue Growth	-2.47%	-13.52%	11.51%
Total Product Revenue	5.19B	5.08B	4.77B
Total Product Revenue Growth	2.09%	6.41%	15.57%
Other Product Revenue	22.00M	21.00M	17.00M
Other Product Revenue Growth	4.76%	23.53%	13.33%
Revenue (Total)	5.89B	5.10B	4.79B
Revenue (Total) Growth	15.44%	6.47%	15.56%

EBIT

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Vision Care Segment Profit	875.00M	849.00M	808.00M
Vision Care Segment Profit Growth	3.06%	5.07%	17.27%
Surgical Segment Profit	34.00M	18.00M	44.00M
Surgical Segment Profit Growth	88.89%	-59.09%	-12.00%
Ophthalmic Pharmaceuticals Segment Profit	313.00M	258.00M	256.00M
Ophthalmic Pharmaceuticals Segment Profit Growth	21.32%	0.78%	6.22%
Corporate Segment Profit	-666.00M	-679.00M	-614.00M
Amortization of Intangible Assets	-248.00M	-258.00M	-288.00M
Net Other Expense	-79.00M	-75.00M	-44.00M
Operating Income (Other)	-26.49M	-	-
Operating Income (Total)	202.51M	113.00M	162.00M
Operating Income (Total) Growth	79.21%	-30.25%	24.62%

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Vision Care Revenue Change in Constant Currency	5.00%	10.00%
Surgical Revenue Change in Constant Currency	6.00%	11.00%
Ophthalmic Pharmaceuticals Revenue Change in Constant Currency	4.00%	45.00%
Total Revenue Change in Constant Currency	6.00%	17.00%

Data Source: Fiscal.ai Last updated: Apr 29, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 24, 2026

Data Sources Report a data error